Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | SOD1 | P00441 | 1/20 | 0.41 |
| ▸ | RHOC | P08134 | 1/20 | 0.40 |
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5725598 | 0.86 | GPR84 (0.45) | GPR84SOD1RHOCRHOAIDO1 | |
| SCHEMBL9215275 | 0.83 | L3MBTL1 (0.55) | L3MBTL1USP2LMNAHTTMRGPRX4 | |
| SCHEMBL8955457 | 0.81 | PDK2 (0.43) | GPR84SOD1RHOCRHOAHDAC3 | |
| SCHEMBL17233207 | 0.81 | NOS1 (0.52) | NOS1MRGPRX4 | |
| SCHEMBL6750419 | 0.81 | NOS1 (0.52) | NOS1MRGPRX4 | |
| SCHEMBL15519689 | 0.81 | PDK2 (0.43) | GPR84SOD1RHOCRHOAHDAC3 | |
| SCHEMBL9248280 | 0.81 | PDK2 (0.43) | GPR84SOD1RHOCRHOAHDAC3 | |
| SCHEMBL4104367 | 0.81 | NOS1 (0.52) | NOS1MRGPRX4 | |
| SCHEMBL31706291 | 0.81 | NOS1 (0.52) | NOS1MRGPRX4 | |
| SCHEMBL8778582 | 0.81 | GPR84 (0.42) | GPR84SOD1RHOCRHOAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
| EP-1480966-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | Exonhit Therapeutics S.A. (FR) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074508-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | EXONHIT THERAPEUTICS SA (FR) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | GPR84 3854/4885SOD1 3566/4885RHOC 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.